The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

The Global Food Allergy Market was valued at approximately USD 36.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.9% over the forecast period 2024-2034. Read the ...

The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

EMA committee recommends approval of Sanofi & Regeneron’s Dupixent to treat eosinophilic esophagitis in children as young as 1 year old: Paris Monday, September 23, 2024, 11:00 ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) ...

AM(IST)on Monday in an upbeat market. Glenmark Pharmaceuticals Ltd.(up 6.99 per cent), Mankind Pharma Ltd.(up 3.47 per cent), ...

Global Necrotizing Fasciitis Market is valued at approximately USD 260.03 million in 2023 and is anticipated to grow at a robust compound annual growth rate (CAGR) of 6.88% over the forecast period ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...